CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company focused on engineered chimeric engulfment receptor T cell (CER-T) therapies for oncology indications. The company became publicly traded through its merger with Phoenix Biotech Acquisition Corp (PBAX), a blank-check company sponsored by Phoenix Biotech Sponsor LLC that completed its IPO in 2021. CERO filed an 8-K with the SEC on February 6, 2024, reflecting activity following the consummation of the de-SPAC business combination. The combined company operates in the biotechnology and cell-therapy sector with shares listed on Nasdaq under the ticker CERO. For comprehensive filing history, sponsor details, and deal analytics on CERO and hundreds of other SPAC transactions, sign up for full data access at SpacDesk.